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Abstract The present study focuses on the expression level of
N-myristoyl transferase (NMT) in the course of human
immunodeficiency virus type-1 (HIV-1) infection. HIV-1 struc-
tural proteins were gradually expressed during the process of
infection of the human T-cell line CEM, whereas the expression
levels of NMT subsequently decreased under the same condi-
tions. In addition, the chronically HIV-1-infected T-cell line
CEM/LAV-1 exhibited low expression levels of NMT. We
hypothesize that the decrease in the expression level of NMT due
to HIV-1 infection may be related to the virus’ strategy that
leads to its persistent replication. ß 2001 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Human immunode¢ciency virus type-1 (HIV-1) utilizes var-
ious biological and biochemical machineries of the host cell to
replicate itself [1,2]. Protein N-myristoylation is one of the
crucial machineries by which HIV-1 gag [3^5] and Nef [6]
exhibit appropriate functions for survival [7^10]. Protein
N-myristoylation, which was discovered in the catalytic sub-
unit of adenosine 3P,5P-phosphate-dependent protein kinase
type-II [11,12], involves cotranslational and post-translational
acylation of the NH2-terminal glycine residues of a number of
cellular and viral proteins with myristic acid [13], which is
catalyzed by N-myristoyltransferase (NMT) (EC 2.3.1.9.7)
[14]. NMT is essential for the survival of eukaryotes, since
disruption of NMT expression caused recessive lethality and
developmental defects in yeast [15] and Drosophila [16], re-
spectively. Thus, human NMT (hNMT) is considered to be
one of the key proteins for both HIV-1 and its host cell.
Although the biological state of the host cell is altered by
HIV-1 infection, leading to apoptosis [17], and inadequate
immunoresponses [18], in which the expression levels of
many-sided host genes change [19^21], there is no such report
related to hNMT in HIV-1-infected host cells.
In this study, we focus on the expression of hNMT in the
process of HIV-1 infection at the protein level. We prepared
anti-NMT monoclonal antibody (mAb) and detected hNMT
in acute HIV-1-infected cells and chronically infected cells by
Western blot analysis. As a result, the isozymes of hNMT
were detected, expression levels of which were subsequently
decreased by HIV-1 infection, in contrast to our expectations.
2. Materials and methods
2.1. Materials
The reagents used in the study were obtained from the following
sources: hNMT expression plasmid (pBB218) was a kind gift from
Dr. J.I. Gordon (Washington University School of Medicine); RPMI
1640 medium was from Nissui Seiyaku Co. (Tokyo, Japan); and HIV-
1-positive human plasma was a kind gift from the Chemo-Sero-Ther-
apeutic Research Institute (Kumamoto, Japan).
2.2. Preparation of anti-NMT mAb
The antigen peptide, the sequence of which was based on residues
388^394 (GIGDGNL) of the cloned hNMT sequence [22], was syn-
thesized and then coupled with multiple antigen peptide (MAP1,
Perkin-Elmer, Applied Biosystems Division, Foster City, CA, USA)
using Fmoc chemistry. Female Balb/c mice were immunized intraper-
itoneally with GIGDGNL-MAP1 in Freund’s adjuvant at 1 week
intervals and administered an intravenous boost of GIGDGNL-
MAP1 3 days prior to splenectomy. Hybridomas were generated by
a standard method in which splenocytes were fused with P3U1 cells
and selected in hypoxanthine-, aminopterin-, and thymidine-supple-
mented media. In the screening process, supernatants were tested for
reactivity to GIGDGNL-Multi-Pin-Block1. Hybridomas that pro-
duced the most potent supernatants were then cloned by the limiting
dilution method.
2.3. Antibody speci¢city
The competitors (GIGDG, GIGD, GNLQ, and GDGNLQ) used
were synthesized using Fmoc chemistry. Antibody speci¢city was de-
termined by enzyme-linked immunosorbent assay (ELISA) as previ-
ously described [23].
2.4. Expression of recombinant hNMT
Escherichia coli JM101 with hNMT expression plasmid (pBB218)
[22] was grown at 37‡C in LB medium containing 100 Wg/ml ampicillin
to an A600 value of V0.8 and hNMT was induced with nalidixic acid
(50 Wg/ml) at 37‡C for 3 h. The bacterial cells were harvested by
centrifugation at 5000Ug for 10 min. The bacterial cells were sus-
pended in cold lysis bu¡er (30 mM MES, 1 mM EDTAW2Na, 50
mM KCl, 50 mM 2-mercaptoethanol, and 1 mM p-APMSF) and
homogenized in a Dounce homogenizer. The bacterial suspension
was subjected to 20 cycles of vortexing with glass beads for 15 s
and then allowed to stand on ice for 45 s. The lysate was centrifuged
at 14 000Ug for 30 min at 4‡C, and the supernatant was subjected to
Western blot analysis.
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2.5. Cell culture and HIV-1 preparation
A human T-cell line, CEM, and a chronically HIV-1-infected T-cell
line, CEM/LAV-1, were maintained at 37‡C in RPMI 1640 medium
supplemented with 10% fetal calf serum (100 IU/ml of penicillin and
100 Wg/ml of streptomycin) in 5% CO2 [24].
Preparation of infectious HIV-1 (LAV-1 strain) and titration of
infectivity were performed as described [25].
2.6. Acute HIV-1 infection and cell lysis
CEM cells (2U105 cells/ml, 10 ml) were infected with HIV-1 at a
multiplicity of infection (m.o.i.) of 0.01, incubated for 1 h at 37‡C in
5% CO2, washed once with phosphate-bu¡ered saline (PBS)(3), and
resuspended in RPMI 1640 medium. The cells were incubated for 0,
24, 28, 72 or 96 h at 37‡C in 5% CO2, washed twice with PBS(3) and
lysed as previously described [7]. Cell viability was determined by the
trypan blue dye exclusion method.
2.7. Western blot analysis
The samples were separated by SDS^PAGE [26] with polyacryl-
amide gel (MULTIGEL 4/20, Daiichi Pure Chemicals Co., Ltd., To-
kyo, Japan) and the separated proteins subsequently electroblotted
onto a polyvinylidene di£uoride membrane (Immobilon, Millipore
Corporation, Bedford, MA, USA). Antigens were probed with anti-
NMT mAb followed by anti-mouse IgG conjugated with horseradish
peroxidase, probed with HIV-1-positive human plasma followed by
anti-human IgG conjugated with horseradish peroxidase, or probed
with anti-actin IgM followed by anti-mouse IgM conjugated with
horseradish peroxidase (Actin (Ab-1) kit, Oncogene Research Prod-
ucts, Boston, MA, USA) and visualized by chemiluminescence (Re-
naissance0, NEN1 Life Science Products, Inc., Boston, MA, USA) or
0.03% 3,3P-diaminobenzidine tetrahydrochloride staining, respectively.
3. Results
The immunotiter of the antibody raised against
GIGDGNL-MAP1, the sequence of which was based on res-
idues 388^394 (GIGDGNL) of the cloned hNMT sequence
[22], was determined by ELISA with GIGDGNL-Multi-Pin-
Block1. Fig. 1A shows the relative percentages of
GIGDGNL-Multi-Pin-Block1 bound to the antibody in the
presence of log dilutions of the competitor peptides (GIGDG,
GIGD, GNLQ, GDGNLQ, and GIGDGNL-MAP1).
GIGDGNL-MAP1-Block1 displaced strongly the binding
of the antibody to GIGDGNL-Multi-Pin, whereas almost
no e¡ect was observed with the other competitors. The results
suggest that the entire moiety of GIGDGNL is essential for
recognition by the antibody.
To investigate whether the antibody could react with
hNMT, hNMT-expressed [22] and -unexpressed E. coli
(JM101) lysates were subjected to Western blot analysis with
the antibody. As shown in Fig. 1B, a major band of 57 kDa
was speci¢cally detected in the hNMT-expressed E. coli but
not in the hNMT-unexpressed E. coli. The result indicates
that the antibody can recognize hNMT in immunoblot anal-
ysis.
To investigate the expression of HIV-1 proteins in acute
infection, CEM cells were infected with HIV-1, and the viral
proteins were detected by Western blot analysis using HIV-1-
positive human plasma. HIV-1 Pr55, p41, p24 and p17 were
detected weakly at 48 h post-infection (p.i.) (Fig. 2A, lane 3)
and strongly at 72 h and 96 h p.i. (Fig. 2A, lanes 4 and 5), the
same as CEM/LAV-1 (Fig. 2A, lane 6).
Under the same conditions, the expression of hNMT was
examined by Western blot analysis using the prepared anti-
NMT mAb. In CEM cells, four immunoreactive bands were
detected, which had apparent molecular masses of 46 kDa, 57
kDa, 63 kDa, and 88 kDa (Fig. 2B, lane 1). During the pro-
cess of infection of HIV-1 in CEM cells, the expression levels
of both 46 kDa and 57 kDa proteins were immediately down-
regulated within 24 h p.i. (Fig. 2B, lane 2), whereas that of the
63 kDa protein decreased gradually up to 96 h p.i. (Fig. 2B,
lanes 1^5). On the other hand, the expression level of the 88
kDa protein was up-regulated from 24 h to 72 h p.i. (Fig. 2B,
lanes 2^4), followed by down-regulation at 96 h p.i. (Fig. 2B,
lane 5). Western blot analysis with the antibody of the chroni-
cally HIV-1-infected T-cell line CEM/LAV-1 revealed the low
expression levels of 46 kDa, 57 kDa, 63 kDa, and 88 kDa
proteins (Fig. 2B, lane 6). This pro¢le was similar to that of
CEM cells at 96 h p.i. (Fig. 2B, lane 5).
To normalize for the same protein contents in the samples,
a cytoskeletal protein, actin, was detected under the same
conditions by Western blot analysis using anti-actin mAb,
the change of expression level of which due to HIV-1 infection
has not been reported so far. As shown in Fig. 2C, the
amount of actin in samples from HIV-1-uninfected, acutely
infected, and chronically infected CEM cells is constant.
4. Discussion
hNMTs, the products of host genes, play an important role
in HIV-1 replication, because HIV-1 gag precursor [3^5] and
Nef [6] are N-myristoylated in HIV-1-infected cells, which is
essential for gaining viral infectivity and membrane associa-
tion [7^10], respectively. Thus, hNMT is indispensable to the
replication of HIV-1, which makes us expect that the expres-
sion of hNMT may be accelerated or at least maintained upon
HIV-1 infection. Therefore, we prepared anti-NMT mAb and
detected hNMT in acutely and chronically HIV-1-infected
cells.
In uninfected CEM cells, four immunoreactive bands were
detected by Western blot analysis using anti-NMT mAb (Fig.
2). Although the 88 kDa protein recognized by the antibody
Fig. 1. Antibody speci¢city. A: Relative percentages of GIGDGNL-
Multi-Pin-Block1 bound to the antibody were determined in the
presence or absence of competitors. Competitors used were:
GIGDG (a) ; GIGD (b) ; GNLQ (E) ; GDGNLQ (F) ; GIGDGNL-
MAP1 (O). B: hNMT was expressed in E. coli JM101 and then
lysed. The lysates were subjected to SDS^PAGE (4^20%) followed
by Western blot analysis using the antibody. Other experimental de-
tails are described in Section 2. Lysates: lane 1, JM101; lane 2,
JM101 expressing hNMT. Molecular markers are shown on the left.
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has not been identi¢ed as hNMT so far, the protein that
shows a change in expression level upon infection has at-
tracted our attention and is now being investigated in our
laboratory to determine its identity. Taking the apparent mo-
lecular masses into consideration, the three major protein
bands of 46 kDa, 57 kDa, and 63 kDa seem to correspond
to NMTS, NMTM, and NMTL, respectively, that were re-
ported by McIlhinney et al. [27]. NMTL and NMTM are
formed by the initiation of translation from the ¢rst and the
second methionine residues, respectively. NMTS is the form
resulting from the alternative splicing of mRNA. Alterna-
tively, it may be argued that one of the three major bands
is from hNMT2 [28], because it also contains the epitope
recognized by the antibody. Although it is still not possible
to distinguish hNMT1 from hNMT2, the expression levels of
all isozymes of hNMT recognized by the antibody appear to
be decreased by HIV-1 infection, in contrast to our previous
expectation. The decrease in the hNMT expression level upon
HIV-1 infection contrasts the high expression level of the viral
proteins in both acutely HIV-1-infected CEM cells and
chronically infected CEM/LAV-1 cells, whereas the expression
level of actin is constant (Fig. 2). The down-regulation of both
46 kDa and 57 kDa proteins within 24 h p.i. is striking be-
cause of the absence of the expression of viral antigens at this
time and the small percentage of infected cells. Since it has
been con¢rmed by £ow cytometric analysis using anti-gp120
antibody that 93.4% of the total number of cells are attached
by virion with gp120 1 h after the inoculation at a m.o.i. of
0.01 (data not shown), the interaction of gp120 with CD4 or
CXCR4, which can induce signal transduction [29,30], may be
related to the immediate down-regulation of hNMTs.
As the viabilities of CEM cells at 96 h p.i. and CEM/LAV-1
cells are 98^99% (data not shown), the low expression level of
hNMT appears to have no e¡ect on cell growth. Moreover,
the low expression level of hNMT seems to be su⁄cient for
viral replication, because there are reports that only a rela-
tively small proportion of the total gag molecules need to be
myristoylated for e⁄cient virus-like particle budding [31] and
that HIV-1 gag is substantially N-myristoylated in CEM/
LAV-1 cells, from which infective virus is produced [3,4].
What is the biological and virological signi¢cance of the
lowered expression level of hNMT upon HIV-1 infection?
Since NMT catalyzes N-myristoylation for inducing particular
proteins to exhibit their intrinsic functions, the expression
level of NMT may determine the characteristics of a cell.
Ryo et al. reported that 53 cellular genes were di¡erentially
expressed upon HIV-1 infection of human T-cell line Molt4
cells [19]. They also indicated that genes with up-regulated
expression levels mainly comprised those that accelerated
HIV-1 replication, whereas genes with down-regulated expres-
sion levels were involved in the defense against apoptosis and
the regulation of basic cellular function. We believe that their
results are valid. However, since hNMT is clearly important
for both HIV-1 replication and basic cellular function, their
conclusions seem to be inapplicable to the case of hNMT with
HIV-1 infection. Assuming that the virus attempts to take
advantage of its e⁄cient replication at all times, a state of
persistent infection without cell death is reasonable for viral
propagation. Zha et al. recently reported that post-transla-
tional and post-proteolytic N-myristoylation of BID(p15) oc-
curs when inactive BID(p22) is cleaved o¡ by caspase-8 [32],
which serves as a switch that activates BID-induced release of
cytochrome c and cell death. Furthermore, HIV-1 Tat induces
the up-regulation of caspase-8, which results in an increase in
sensitivity to apoptosis signals [33]. It follows from the above
discussion that if the low expression level of hNMT is insu⁄-
cient for N-myristoylation of BID(p15) in HIV-1-infected
cells, induction of apoptosis-mediated caspase-8 will not oc-
cur, thereby leading to chronic infection. The decrease in the
hNMT expression level may contribute in part to the inad-
equate immunoresponse in HIV-1-infected individuals, be-
cause N-myristoylation of src family kinases Lck and Fyn is
Fig. 2. Expression of HIV-1 structural proteins, hNMT, and actin in acutely and chronically HIV-1-infected CEM. CEM cells infected with
HIV-1 at a m.o.i. of 0.01 were incubated for 0, 24, 28, 72 or 96 h at 37‡C in 5% CO2. The cells were lysed and the lysates were subjected to
SDS^PAGE (4^20%) followed by Western blot analysis using HIV-1-positive human plasma (A), anti-NMT mAb (B) or anti-actin mAb (C).
Other experimental details are described in Section 2. Cell lysates: lane 1, uninfected CEM; lane 2, CEM at 24 h p.i. ; lane 3, CEM at 48 h
p.i. ; lane 4, CEM at 72 h p.i. ; lane 5, CEM at 96 h p.i. ; lane 6, CEM/LAV-1. Molecular markers are shown on the left.
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required for T-cell receptor-mediated signal transduction that
leads to the activation of T-cells [34,35]. Boutin et al. [36]
reported that NMT in the cytosolic fraction of CCRF-CEM
cells, a human acute lymphoblastic leukemia cell line, most
highly recognized a peptide substrate derived from HIV-1 gag
from among the many peptide substrates derived from cellular
and viral proteins, which are potential substrates for NMT.
These data suggest that HIV-1 gag has priority over other
potential substrates in the host cell for N-myristoylation,
even at a low expression of NMT. To con¢rm this hypothesis,
we must investigate whether the reduction of myristoylated
proteins of the host cell by HIV-1 infection occurs, which
gives a substantial advantage to viral replication.
Further work is under way to clarify the biological signi¢-
cance and the mechanism of the down-regulation of hNMT
expression with HIV-1 infection, which may lead to ¢nding a
novel target for AIDS therapy.
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